Independent
Tenure on this board
4.8 yrs
Meeting calendar
PODD · Annual meeting · Wednesday, May 20, 2026
Insulet Corp
3 nominees · 3 ballot items.
Election of three Class I directors; advisory (non-binding) approval of executive compensation (“Say-on-Pay”); and ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal 2026.
Market cap
$11.4B
1Y TSR
-46.7%
Board grade
C-
Record date
Mar 23, 2026
Filing
DEF 14A
Meeting concluded · May 20, 2026
Follow how the vote landed and what changed on Insulet Corp’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot3
- 1
Election of three Class I Directors
ManagementBoard: FORElect three Class I directors (Luciana Borio, Michael R. Minogue, and Timothy C. Stonesifer) to serve three-year terms until the 2029 annual meeting.
- 2
Advisory Vote to Approve Executive Compensation (Say-on-Pay
ManagementBoard: FORNon-binding, advisory vote to approve the compensation of certain executive officers as disclosed in the proxy statement.
More detail
This management proposal seeks a non-binding advisory approval of the company’s executive compensation as disclosed in the proxy statement. Management (the Board and the Talent and Compensation Committee) asks shareholders to endorse the compensation program for named executive officers, arguing it aligns pay with performance, emphasizes long-term incentives (PSUs, RSUs, options), ties annual incentives to Adjusted Revenue, Adjusted EBIT and new customer starts, and uses robust governance practices (independent committee, independent advisor, clawback policy, stock ownership guidelines). The proposal provides shareholders with an opportunity to express views on compensation; management notes past high support (~93% in 2025) and commits to consider vote results in future decisions. The vote is advisory, not binding, and requires a simple majority of votes cast; abstentions and broker non-votes are not counted as votes cast. The Board recommends a vote FOR, citing alignment with strategy, retention and pay-for-performance design, and governance safeguards.
- 3
Ratification of PricewaterhouseCoopers LLP as Independent Registered Public Accounting Firm for Fiscal 2026
ManagementBoard: FORRatify the Audit Committee’s appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for fiscal year 2026.
Director elections
Nominees on the ballot3
Independent
Tenure on this board
9.0 yrs
Independent
Tenure on this board
2.5 yrs
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 6.6% | 4,579,274 | $961M |
| 2 | VANGUARD PORTFOLIO MANAGEMENT LLC | 5.0% | 3,449,987 | $724M |
| 3 | STATE STREET CORP | 4.4% | 3,042,454 | $638M |
| 4 | BlackRock, Inc. | 4.3% | 2,992,067 | $628M |
| 5 | FMR LLC | 4.1% | 2,857,158 | $600M |
| 6 | T. Rowe Price Investment Management, Inc. | 2.6% | 1,815,742 | $381M |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 2.6% | 1,806,393 | $378M |
| 8 | Capital Research Global Investors | 2.4% | 1,669,556 | $350M |
| 9 | AMERICAN CENTURY COMPANIES INC | 2.3% | 1,591,410 | $334M |
| 10 | AQR CAPITAL MANAGEMENT LLC | 2.3% | 1,565,731 | $329M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Insulet Corp’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Apogee Therapeutics IncAPGE
Special meeting·Aug 11, 2026·$10.1B
Jazz Pharmaceuticals PLCJAZZ
Annual meeting·Jul 23, 2026·$15.5B
Amneal Pharmaceuticals IncAMRX
Special meeting·Jul 31, 2026·$5.7B
Doximity IncDOCS
Annual meeting·Aug 27, 2026·$3.9B
Organon & CoOGN
Special meeting·Jul 23, 2026·$3.6B
Haemonetics CorpHAE
Annual meeting·Jul 24, 2026·$3.5B
Reference
Frequently asked questions
- When is the Insulet Corp 2026 annual meeting?
- Insulet Corp (PODD) holds its 2026 annual shareholder meeting on Wednesday, May 20, 2026.
- What is the record date for the Insulet Corp 2026 meeting?
- The record date for the Insulet Corp 2026 meeting is Monday, March 23, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Insulet Corp's 2026 meeting?
- The board is presenting 3 director nominees at the Insulet Corp 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Insulet Corp 2026 meeting?
- Shareholders will vote on 3 proposals at the Insulet Corp 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.